PapersPMID:26400476
A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“Median (interquartile range, IQR) of ALT levels in the silymarin and placebo groups were 32 (20, 184) and 35 (15, 415) IU/L, which were not significantly different (p = 0.455).”
- Study
- RCT
- Duration
- 4 weeks
- Interests
- Industry funded
- Dose studied
- 140 mg three times daily with the antituberculosis drugs
- Population
- Adults with newly diagnosed pulmonary tuberculosis, all receiving isoniazid, rifampicin, pyrazinamide and ethambutol; ALT at week 4
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Adults with newly diagnosed pulmonary tuberculosis starting standard antituberculosis therapy (silymarin 140 mg tablets, a milk thistle extract standardised to silymarin)
- Participants
- 55
- Comparator
- placebo
- Duration
- 28 days
- Endpoints measured
- 14